Palbociclib,2757498-64-7

价格询价

品牌MedChemExpress(MCE)
产地美国
货号HY-50767D
更新日期2025年12月05日

MedChemExpress LLC

品牌商

14 年钻石会员

Palbociclib orotate

CAS No. : 2757498-64-7

MCE 国际站：Palbociclib orotate

产品活性：Palbociclib (PD 0332991) orotate 是一种具有口服活性的 CDK4 和 CDK6 选择性抑制剂，IC₅₀ 值分别为 11 nM 和16 nM。Palbociclib orotate 对癌细胞具有抗增殖活性，并诱导其细胞周期阻滞，可用于 HR 阳性和 HER2 阴性乳腺癌，以及肝细胞癌的相关研究。

研究领域：Cell Cycle/DNA Damage

作用靶点：CDK

In Vitro: Palbociclib (0-1 μM, 24 h) orotate inhibits retinoblastoma phosphorylation at Ser⁷⁹⁵ in MDA-MB-435 cells with an IC₅₀ value of 0.063 μM, and obtains similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation in the Colo-205 colon carcinoma.
Palbociclib (0-10 μM, 24 h) orotate arrests MDA-MB-453 cells exclusively in G1 phase.
Palbociclib (500 nM, 7 days) orotate increases expression of homologous genes (H2d1, H2k1, and B2m) in MDA-MB-453 and MDA-MB-361 cells.
Palbociclib (0-1 μM, 6 days) orotate inhibits growth of several luminal ER-positive as well as HER2-amplified breast cancer cell lines, with IC₅₀ values ranging from 4 nM to 1 μM.
Palbociclib (0-1 μM, 3 days) orotate inhibits the proliferation of human liver cancer cell lines with IC₅₀ values ranging from 0.01 μM to 3.49 μM, and induces a reversible cell cycle arrest.

In Vivo: Palbociclib (oral adminstration, 75 or 150 mg/kg, daily for 14 days) orotate produces rapid tumor regressions and delays tumor growth.
Palbociclib (oral adminstration, 90 mg/kg, daily for 12 days) orotate reduces Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes in tumor-free mice, demonstrating the tumor-independent effects.
Palbociclib (oral administration, 100 mg/kg, daily for 1 week) orotate has potent antitumour effects in genetically engineered mosaic mouse model of liver cancer.